Peginesatide
Omontys (peginesatide) is a protein pharmaceutical. Peginesatide was first approved as Omontys preservative free on 2012-03-27. The pharmaceutical is active against erythropoietin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J0890 | Injection, peginesatide, 0.1 mg (for esrd on dialysis) |
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 5 | 5 | 6 | 8 | 22 |
| Macular edema | D008269 | 2 | 3 | 2 | 2 | 3 | 10 | ||
| Choroidal neovascularization | D020256 | — | — | 1 | 1 | 1 | 3 | ||
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | 1 | — | 2 | — | 3 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | 1 | 1 | 1 | — | — | 3 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 2 | — | — | 2 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Regional blood flow | D012039 | — | — | — | — | 1 | 1 | ||
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEGINESATIDE |
| INN | peginesatide |
| Description | Peginesatide (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.
|
| Classification | Protein |
| Drug class | PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer; peptides: erythropoiesis stimulating agents and/or erythropoietin mimetic peptides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 913976-27-9 |
| RxCUI | 1248798 |
| ChEMBL ID | CHEMBL2107866 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08894 |
| UNII ID | JX56W9N61Q (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 189 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
478 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more